Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 682 | Poster Presentation | Antibody-mediated Blockade of Interleukin-10 Receptor-alpha Promotes the Activation of Immune Cells from in vitro Dissociated Tumor Samples | Alexey Berezhnoy, PhD, DVM; Kalpana Shah, BS; Daorong Liu; Peter Lung, BS, HT (ASCP); Vatana Long; Kurt Stahl, BS; Douglas Smith, PhD; Francine Z. Chen, MD; Hua Li, MS; Jonathan Li, PhD; Ralph F. Alderson, PhD; Valentina Ciccarone, PhD; James K. Tamura, PhD; Ezio Bonvini, MD; Gundo Diedrich, PhD; Paul A. Moore, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Checkpoint blockade; Immune suppression; Immune tolerance; Monocyte/Macrophage; Myeloid cells; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 683 | Poster Presentation | A novel mechanism of Neuropilin-1 inhibition results in improved tumor growth inhibition in vivo | Daniel Blom; Shalini Sethumadhavan; Chengfeng Merriman; Katherine Molloy; alexandria Fink; Shan Lou; andrew rogantino; Ameya Apte; Mandana abbassi; Tiffany Liao; Hongyue Dai; aaron fulgham; Jonathan Hurov; Pearl Huang; | Novel Single-Agent Immunotherapies | Angiogenesis; Antibody; MDSC; Monocyte/Macrophage; Regulatory T cell (Treg cell); Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 684 | Poster Presentation | A low affinity bivalent mesothelin-binding MATCH4 multispecific T cell engager increases cytotoxic selectivity for high mesothelin expressing cells | Bithi Chatterjee, PhD; Alexandre Simonin, PhD; Daniel Snell, PhD; Tea Gunde, PhD; Christian Hess, PhD; Matthias Brock, PhD; Stefan Warmuth, PhD; Christopher Weinert, PhD; Niels Kirk; Dania Diem; Naomi Flückiger; Robin Heiz; Benjamin Küttner; Dana Mahler; Diego Morenzoni; Sandro Wagen; Julia Zeberer; David Urech, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 685 | Poster Presentation | A Highly Selective and Potent HPK1 Inhibitor Enhances Immune Cell Activation and Induces Robust Tumor Growth Inhibition in a Murine Syngeneic Tumor Model | David Ciccone, PhD; Vad Lazari; Ian Linney; Michael Briggs; Samantha Carreiro; Joshua McElwee; Ian Waddell; Chris Hill; Christine Loh; Peter Tummino; Alan Collis; Neelu Kaila; | Novel Single-Agent Immunotherapies | Antigen presenting cells; B cell; Checkpoint blockade; Cytokine; Dendritic cell; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs) |
| 686 | Poster Presentation | Preclinical characterization of a novel therapeutic antibody targeting LILRB2 | Maria Jose Costa, PhD; Ryan Stafford, PhD; Zhiqiang Ku, PhD; Jing-Tyan Ma; Krista McCutcheon; Xiaoye Liu, PhD; Heyu Chen, PhD; Kyu Hong; Tao Huang, PhD; Ningyan Zhang, PhD; Zhiqiang An, PhD; Cheng Cheng Zhang, PhD; X. Charlene Liao, PhD; An Song, PhD; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Checkpoint blockade; Immune suppression; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor evasion; Tumor microenvironment |
| 687 | Poster Presentation | Enhancement of anti-tumor immunity by ICT01: a novel g9d2 T cell-activating antibody targeting Butyrophilin-3A (BTN3A) | Aude de Gassart, PhD; Patrick Brune; Suong LE; Sophie Agaugue; Emmanuel Valentin, PhD; Remy Castellano; Jennifer Sims; Alem Truneh; Daniel Olive, M.D., Ph.D.; Rene Hoet; | Novel Single-Agent Immunotherapies | Antibody; T cell; T cell lineages |
| 688 | Poster Presentation | In vivo expansion of gamma delta T cells by a CD19-targeted butyrophilin heterodimer leads to elimination of peripheral B cells | Suresh De Silva, Ph.D.; George J. Fromm, Jr., Ph.D.; Louis E. Gonzalez, Ph.D.; Arpita Patel, BSc; Kyung J. Yoon; Zachery Opheim; Robert Farmer; Dean Chamberlain, Ph.D.; Taylor H. Schreiber, MD, PhD; | Novel Single-Agent Immunotherapies | B cell; Bispecifics; T cell |
| 689 | Poster Presentation | ATRC-101 Drives Potent Single-Agent Activity in Mouse Syngeneic Tumor Models via a Novel Cellular Mechanism of Action | Yvonne Leung, Ph.D.; Nikhil Vad, PhD; Anne Ye, PhD; Daniel R. Santos, MS; Wei Cao; Cathrin Czupalla, Ph.D.; John Vivian, PhD; Carlene Williams; Judevin Sapugay, BS; Michael Harbell, M.S.; Shaun M. Lippow, Ph.D.; Chantia Carroll, BS; Lance Kates, BS; Benjamin Haugen, BS; Gary Bolton, BS; Mark Armanini, BS; Iraz T. Aydin, PhD; Mark Whidden, PhD; Mauricio Velasco-Delgado, MS; Felix Chu, MS; Erin Wechsler, PhD; Ngan A. Nguyen, PhD; William H. Robinson, MD PhD; Tito A. Serafini, PhD; Daniel Emerling, PhD; Norman M. Greenberg, PhD; Amy Manning-Bog, PhD; Alexander Scholz, PhD; | Novel Single-Agent Immunotherapies | Chemokine; Cytokine; Dendritic cell; Myeloid cells; RNA; T cell; T cell lineages; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 690 | Poster Presentation | CD122-selective IL-2 complexes treat ovarian carcinomas, induce Treg fragility and promote T cell stem cells | Yilun Deng, MD, PhD; Justin M. Drerup; Xinyue Zhang; Ryan M. Reyes, BS; Jenny A. Mendez; Aravind Kancharla, MS; Myrna G. Garcia, BS; Haiyan Bai; Alvaro S. Padron, PhD; Harshita B. Gupta, PhD; Tyler J. Curiel, MD, MPH; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Cytokine; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs) |
| 691 | Poster Presentation | MDK-271: A dual function molecule consisting of empirically-designed peptidyl agonists of IL-2/15Rβγc and IL-7Rαγc, unrelated to IL-2, IL-15, or IL-7, incorporated into a bispecific Fc fusion protein | William J. Dower, PhD; Steven E. Cwirla; Alice V. Bakker, BA; Praechompoo Pongtornpipat, MS; Blake M. Williams, MS; Prarthana Joshi, ME; Sandra M. Wang, BSc; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Novel Single-Agent Immunotherapies | Bispecifics; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 692 | Poster Presentation | AMV564, a clinically active T cell engager, induces a target-dependent adaptive immune response | Sterling C. Eckard, PhD; Aurelien Sarde; Li Mei; Curtis Ruegg, PhD; Patrick Chun, MD; Victoria Smith, PhD; | Novel Single-Agent Immunotherapies | Clinical trial; Immune suppression; MDSC; Myeloid cells; Solid tumors; T cell; Targeted therapy |
| 693 | Poster Presentation | APX601, a Novel TNFR2 Antagonist Antibody for Cancer Immunotherapy | Erin L. Filbert, PhD; Sushma Krishnan, MSc in Biology; Ryan Alvarado; George Huang; Francis R. Bahjat; Xiaodong Yang, MD, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; MDSC; Myeloid cells; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 694 | Poster Presentation | NC410 is a Novel Immunomedicine for the Treatment of Solid Tumors | Linjie Tian, PhD; M. Ines Pascoal Ramos, PhD; Emma de Ruiter; Ana Paucarmayta; Eline Elshof; Stefan Willems, MD, PhD; Chang Song, PhD; Zachary Cusumano, PhD; Jason Bosiacki; Linda N. Liu, PhD; Solomon Langermann, PhD; Linde Meyaard, PhD; Dallas B. Flies, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Solid tumors; T cell; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 695 | Poster Presentation | Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice | Loise Francisco-Anderson, PhD; Mary Abdou, BS; Michael Goldberg, PhD; Erin Troy, PhD; Alicia Ballok, PhD; Fabian Romano Chernac, PhD; Maria Sizova, PhD; Krutika Invally, PhD; Shubhra Kashyap, MS; Audrey McBride, BS; Jessica Tsang, BS; Shannon Argueta, PhD; Kristie Barth, PhD; Valeria Kravitz, MS; Holly Ponichtera, PhD; Tyler Rommel, MS; Kevin Huynh, MS; Tanmoy Ganguly, PhD; Mark Bodmer, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Extracellular vesicles/exosomes; TLR; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 696 | Poster Presentation | Brentuximab vedotin, a CD30-directed antibody-drug conjugate, selectively depletes activated Tregs in vitro and in vivo | Bryan M. Grogan, MS; Reice D. James, BS; Michelle Ulrich, BS; Shyra J. Gardai, PhD; Ryan Heiser, PhD; | Novel Single-Agent Immunotherapies | Antibody; Biomarkers; Immune suppression; Leukemia/Lymphoma; Regulatory T cell (Treg cell); T cell; Targeted therapy; Tumor microenvironment |
| 697 | Poster Presentation | Tumor-targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors | Michael Hedvat, PhD; Veronica Zeng, PhD; Juan Diaz, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Irene Leung, PhD; Norm Bartlow, PhD; Charles Bakhit; Matthew Dragovich, PhD; Liz Bogart, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD; Gregory L. Moore, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 698 | Poster Presentation | Targeting HLA-G-mediated immunosuppression with a first-in-class antagonist antibody | Douglas Hodges; Christina M. Kochel, PhD; Michael Totagrande; Jeffrey Jones; Megan Welch; Bradley N. Spatola, PhD; Shelby Joe; John A. Corbin, PhD; Vanessa B. Soros, PhD; Courtney Beers, PhD; Achim K. Moesta, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Immune tolerance; Solid tumors; Tumor evasion; Tumor microenvironment |
| 699 | Poster Presentation | A differentiated anti-OX40 agonist BGB-A445 does not block OX40-OX40L interaction and reveals remarkable anti-tumor efficacy in preclinical models | Ye Liu, Ph.D; Beibei Jiang; Tong Zhang; Zuobai Wang; Yingcai Feng; Haiying Li; Wenfeng Gong; Xing Wang; Yajuan Gao; Xiaosui Zhou; Bo Zhang; Yuan Hong; Jing Wang; Zilin Wang; Hongjia Hou; Hanzi Sun; Xiaomin Song, PhD; Kang Li; Xuesong Liu; | Novel Single-Agent Immunotherapies | Antibody; Costimulation; T cell |
| 700 | Poster Presentation | EphA2/CD137 Bicycle tumor-targeted immune cell agonists (TICAsTM) induce tumor regressions, immunogenic memory, and reprogramming of the tumor immune microenvironment | Kristen E. Hurov, PhD; Johanna lahdenranta, PhD; Gemma Mudd, .; Punit Upadhyaya, PhD; Elizabeth M. Repash, MSc; Jun Ma, MSc; Julia Kristensson, .; Marianna Kleyman; Jessica Kublin; Liuhong Chen; Eric Haines, PhD; Sailaja Battula; Kevin McDonnell, PhD; Philip E. Brandish; Nicholas Keen, PhD; | Novel Single-Agent Immunotherapies | Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 701 | Poster Presentation | Nanoparticulate monobenzone (MBEH) as a potential drug candidate for melanoma | Dinesh Jaishankar, PhD; Steven Henning; Anqi Zhang, PhD; Basar Bilgicer, PhD; SonBinh Nhuyen, PhD; I. Caroline Le Poole, PhD; | Novel Single-Agent Immunotherapies | Neoantigens; Solid tumors; T cell |
| 702 | Poster Presentation | Dual blockade of the PD-1 checkpoint pathway and the adenosinergic negative feedback signaling pathway with a PD-1/CD73 bispecific antibody for cancer immune therapy | Tingting Zhong, MS; Zhaoliang Huang, BSc; Xinghua Pang, BSc; na chen, MD; Xiaoping Jin, PhD; Yu Xia, PhD; Zhongmin Maxwell Wang, PhD; Baiyong Li, PhD; Yu Xia, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Checkpoint blockade; Immune monitoring; Immune suppression |
| 703 | Poster Presentation | Engineered exosomes with altered cellular tropism achieve targeted STING agonist delivery and single-agent tumor control in vivo | Monique Kauke, PhD; Nikki Ross, PhD; Dalia Burzyn; Shelly Martin; Ke Xu; Nuruddeen Lewis; Charan Leng; Su Chul Jang, PhD; Christine McCoy; Stephanie Yu; Kevin Dooley; Sriram Sathyanarayanan, PhD; Jonathan Finn; | Novel Single-Agent Immunotherapies | Antibody; Antigen presenting cells; Dendritic cell; Extracellular vesicles/exosomes; Monocyte/Macrophage; Myeloid cells; Proteomics; Solid tumors |
| 704 | Poster Presentation | Preclinical mechanism of action and pharmacodynamic biomarker studies of DuoBody®-CD3x5T4 in vitro and in vivo in solid cancer models | Kristel Kemper, PhD; Ellis Gielen; Mischa Houtkamp, PhD; Peter Boross; Saskia Burm, PhD; Stefanie A. De Poot; Patrick Engelberts; Bart E. de Goeij; David Satijn, PhD; Kate Sasser, PhD; Esther Breij, PhD; | Novel Single-Agent Immunotherapies | Antibody; Biomarkers; Bispecifics; Cytokine; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 705 | Poster Presentation | Anti-tumor activity of CB-668, a potent, selective and orally bioavailable small-molecule inhibitor of the immuno-suppressive enzyme Interleukin 4 (IL-4)-Induced Gene 1 (IL4I1) | Andrew MacKinnon, PhD; Deepthi Bhupathi; Jason Chen; Tony Huang; Weiqun Li, PhD; Yong Ma; Natalija Sotirovska, MS; Susanne Steggerda, PhD; Winter Zhang; Francesco Parlati, PhD; | Novel Single-Agent Immunotherapies | Immune suppression; Metabolism; Solid tumors; T cell; Tumor microenvironment |
| 706 | Poster Presentation | BT7480, a fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized CD137 agonism and modulation of tumor immune microenvironment | Punit Upadhyaya, PhD; Kristen E. Hurov, PhD; Jessica Kublin; Jun Ma, MSc; Elizabeth M. Repash, MSc; Marianna Kleyman; Julia Kristensson, .; Drasti Kanakia; Fanglei You; Liuhong Chen; Eric Haines, PhD; Sailaja Battula; Kevin McDonnell, PhD; Philip E. Brandish; Johanna lahdenranta, PhD; Nicholas Keen, PhD; | Novel Single-Agent Immunotherapies | Bispecifics; Costimulation; Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 707 | Poster Presentation | Discovery of a novel EP2 and EP4 dual antagonist | Yeri Lee; Hyun Jin Kim; Donggeon Kim, DVM,PhD; Joo Youn Lee; Chang Soo Yun; Hyuk Lee; Young Sook Shin; Soo Bong Han; Sang Kyun Lim; | Novel Single-Agent Immunotherapies | Coinhibition; Dendritic cell; Immune suppression; Inflammation; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 708 | Poster Presentation | Application of a novel mSENS drug delivery technology for mRNA therapeutics | Sojin Lee, Dr.; Joon Young Park; Goo-Young Kim, Ph.D.; Sang Woo Jo; Minhyuk Yun; Hye Yeong Nam; Helen Cho; | Novel Single-Agent Immunotherapies | RNA; Solid tumors; T cell; Tumor antigens; Vaccine |
| 709 | Poster Presentation | Exosome surface display of IL-12 results in tumor-retained pharmacology with superior potency and limited systemic exposure | Nuruddeen Lewis, PhD; Katherine Kirwin; Sonya Haupt; Gauri Mahimkar; Tong Zi; Ke Xu; Kevin Dooley; Su Chul Jang, PhD; Bryan Choi; Andrew Grube; Christine McCoy; Jorge Sanchez-Salazar; Michael Doherty; Scott Estes; Kyriakos Economides; Douglas E. Williams; Sriram Sathyanaryanan, PhD; | Novel Single-Agent Immunotherapies | Cytokine; Extracellular vesicles/exosomes; Immune adjuvant; NK/NK T cell; T cell |
| 710 | Poster Presentation | Development of IL-33 as a novel immunotherapy of cancer | Joshua Zhong; Runzi Sun; Binfeng Lu, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 711 | Poster Presentation | HBM1022, a Novel Anti-CCR8 Antibody Depletes Tumor-infiltrating Regulatory T cells via Enhanced ADCC Activity, Mediates Potent Anti-Tumor Activity with Keytruda | Shuang Lu, MS; Shaoping Hu; Xin Gan; Yongqiang Wang; Chuchu Zhao; Yi Ding; Jinqiu He; Qing Du; Xiaocheng Lv; Beibei Qin; Yun He; Lei Niu; Yuntao Wu; Fei Chen; Yuandong Wang; Yunxing Yang; Yang Cao; Musheng Bao; Jason Noon; Wenhao Yu; Juan Liu; Joe Zhao, PhD; Yiping Rong; Shuang Lu, MS; | Novel Single-Agent Immunotherapies | Antibody; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 712 | Poster Presentation | SBT6290, a systemically administered Nectin-4-directed TLR8 ImmunoTAC (TM) therapeutic, is a potent human myeloid cell agonist for the treatment of Nectin-4-expressing tumors | Heather Metz, PhD; Ty Brender; Brenda Stevens; Damion Winship; Jamie Brevik; Michael Comeau; Monica Childs; Jenny R. Chang; Li-Qun Fan; Hengyu Xu; Jonathan Grey; Jeffrey Adamo; Ben Setter; Ray Carrillo; Sean W. Smith; Phil Tan; Robert E. DuBose; Yvette Latchman, PhD; Peter Baum; Valerie Odegard, PhD; | Novel Single-Agent Immunotherapies | Monocyte/Macrophage; Myeloid cells; Solid tumors; Targeted therapy; TLR; Tumor antigens; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 713 | Poster Presentation | Antibody-based approach of MT1-MMP metalloprotease inhibition results in decreased invasive properties of pancreatic cancer cells | Nikita A. Mitkin, PhD; Alisa M. Gorbacheva; Alina S. Ustiugova; Aksinya N. Uvarova; Kirill V. Korneev; Vsevolod V. Pavshintsev, PhD; Nikita A. Mitkin, PhD; | Novel Single-Agent Immunotherapies | Antibody; B cell; Immune adjuvant; Inflammation; Tumor microenvironment |
| 714 | Poster Presentation | PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors | Gregory L. Moore, PhD; Suzanne Schubbert, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Erik Pong, BS; Lukasz J. Ochyl, PhD; Alex Nisthal, PhD; Seung Chu, PhD; James Ernst, PhD; John R. Desjarlais, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 715 | Poster Presentation | FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, induces LAG-3 shedding resulting in receptor downregulation by T cells via a novel mechanism of action | Michelle Morrow, PhD; Mustapha Faroudi, PhD; Krishnendu Chakraborty, PhD; Wenjia Liao, BSc; Julia Winnewisser, PhD; Claire Seal, PhD; Daniel Gliddon, PhD; Neil Brewis, PhD, DSc; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Checkpoint blockade; Coinhibition; T cell |
| 716 | Poster Presentation | CELL-BASED VIROTHERAPY FOR TARGETING CANCERS | Duong H. Nguyen; Alberto Gomez; Forrest Neuharth; Ashley Alamillo; Thomas Herrmann; Barbara Härtl; Laura Schneider; Ivelina Minev; Boris Minev, MD; Dobrin Draganov, PhD; Antonio F. Santidrian; | Novel Single-Agent Immunotherapies | Solid tumors; Stem cell/cancer-initiating cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 717 | Poster Presentation | AMG 160, a prostate-specific membrane antigen (PSMA)-targeted BiTE® immuno-oncology therapy, is active in models of advanced prostate cancer that are resistant to radioligand therapy | Katharina Lueckerath, Dr.; Julie M. Bailis, PhD; Kyle Current, BA; Mark E. Salvati, PhD; Caius Radu, MD; Johannes Czernin, MD; | Novel Single-Agent Immunotherapies | Bispecifics; Clinical trial; Solid tumors; T cell; Tumor antigens |
| 718 | Poster Presentation | AMG 509, a STEAP1 x CD3 bispecific XmAb® 2+1 immune therapy, exhibits avidity-driven binding and preferential killing of high STEAP1-expressing prostate and Ewing sarcoma cancer cells | Cong Li, PhD; Madeline Fort, PhD; Lingming Liang, MS; Gregory L. Moore, PhD; Matthew J. Bernett, PhD; Umesh Muchhal, PhD; Tao Osgood, BS; Rodolfo Yabut, BA; Sarav Kaliyaperumal, MPH, PhD; John Harrold, PhD; Jude Canon, PhD; Anna Rogojina, PhD; Raushan Kurmasheva, PhD; John R. Desjarlais, PhD; Peter Houghton, PhD; Olivier Nolan-Stevaux, PhD; | Novel Single-Agent Immunotherapies | Antibody; Bispecifics; Chemotherapy; Solid tumors; T cell; Targeted therapy; Tumor antigens |
| 719 | Poster Presentation | CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer | Ryan M. Reyes, BS; Yilun Deng, MD, PhD; Deyi Zhang, PhD; Niannian Ji, PhD; Neelam Mukherjee, PhD; Karen Wheeler, MD PhD; Harshita B. Gupta, PhD; Aravind Kancharla, MS; Myrna G. Garcia, BS; Anand VR. Kornepati, BS; Robert S. Svatek, MD MSCI; Tyler J. Curiel, MD, MPH; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Cytokine; NK/NKT cell; T cell; Tumor microenvironment |
| 720 | Poster Presentation | Targeting MARCO and IL-37R on anti-inflammatory macrophages in lung cancer blocks regulatory T cells and shift balance to support cytotoxic lymphocyte function | Linnéa La Fleur; Johan Botling; Fei He; Catarina Pelicano; Giorgia Palano; Artur Mezheyeuski; Patrick Micke; Jeffrey V. Ravetch, MD, PhD; Mikael Karlsson; Dhifaf Sarhan, PhD; | Novel Single-Agent Immunotherapies | Immune suppression; Myeloid cells; Solid tumors; Targeted therapy; Tumor microenvironment |
| 721 | Poster Presentation | AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection | Remko Schotte, PhD; Julien Villaudy, PhD; Martijn Kedde, PhD; Wouter Pos, PhD; Daniel Go; Christien Fatmawati; Gemma Moiset, PhD; Etsuko Yasuda; Madalina Cercel; Esmay Frankin; Susan van Hal; Pauline M. van Helden, PhD; Els Verdegaal, PhD; Sjoerd H. van der Burg, PhD; Hergen Spits, PhD; Hans van Eenennaam, PhD; | Novel Single-Agent Immunotherapies | Antibody; B cell; Extracellular vesicles/exosomes; Monocyte/Macrophage; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs) |
| 722 | Poster Presentation | Inhibition of Integrin avß8-Mediated TGF-ß Activation with C6D4 Provides Improved Potency and Selectivity vs General TGF-ß Inhibitors for Cancer Immunotherapy | Robert Seed, PhD; Stephen Nishimura, MD; Robert Seed, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 723 | Poster Presentation | Lymph node-targeted AMP-vaccine enables tumor-directed mKRAS-specific immune responses with potent polyfunctional and cytolytic activity | Martin Steinbuck, PhD; Peter C. DeMuth, PhD; Lochana Seenappa, MS; | Novel Single-Agent Immunotherapies | Immune adjuvant; T cell; Vaccine |
| 724 | Poster Presentation | STAT3 inhibition in acute myeloid leukemia cells allows for TLR9-driven differentiation to immunogenic monocytic cells and induction of T-cell mediated immune responses | Yu-Lin Su, PhD; Marcin Kortylewski, PhD; Priyanka Duttagupta, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Bispecifics; Immune suppression; Leukemia/Lymphoma; MDSC; Monocyte/Macrophage; Myeloid cells; RNA; Targeted therapy; TLR |
| 725 | Poster Presentation | Pre-clinical development of TNFR2 ligand-blocking BI-1808 for cancer immunotherapy | Linda Mårtensson, PhD; Mathilda Kovacek; Petra Holmkvist, PhD; Monika Semmrich, PhD; Carolin Svensson; Therese Blidberg; Carl Roos, PhD; Andres McAllister, MD, PhD; Mimoza Demiri, PhD; Marie Borggren, PhD; Ingrid Karlsson, PhD; Björn Frendeus, PhD; Ingrid Teige, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 726 | Poster Presentation | SRF114 is a fully human, CCR8 selective IgG1 antibody that induces destruction of tumor Tregs through ADCC | Andrew C. Lake, PhD; Michael C. Warren, MS; Sonia G. Das, PhD; Christopher C. Wells, BS; Maria Scrivens, BA; Ernest S. Smith, PhD; Vito J. Palombella, PhD; Bijan Etemad-Gilbertson, PhD; Pamela M. Holland, PhD; Austin Dulak, PhD; | Novel Single-Agent Immunotherapies | Antibody; Regulatory T cell (Treg cell); T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| 727 | Poster Presentation | Increased serum levels of EBI3 are associated with poor outcome in hepatocellular carcinoma patients and SRF388, a first-in-class IL-27 blocking antibody, inhibits the growth of murine liver tumors | Matthew P. Rausch, PhD; Devapregasan Moodley, PhD; Marisa O. Peluso, MS; Secil Koseoglu, PhD; Jing Hua, MD, MS; Gege Tan, MA; Ricard Masia, MD PhD; Benjamin H. Lee, MD PhD; Isabelle Cousineau, PhD; Simon Turcotte, MD MSc; John Stagg, PhD; Vito J. Palombella, PhD; Pamela M. Holland, PhD; Jonathan A. Hill, PhD; | Novel Single-Agent Immunotherapies | Antibody; Cytokine; Immune suppression; Myeloid cells; Tumor evasion |
| 857 | Poster Presentation | LAMP1 targeting of the large T antigen of Merkel cell polyomavirus elicits potent CD4+ T cell responses and prevents tumor growth | Claire Buchta Rosean, PhD; Pratima Sinha, PhD; David M. Koelle, MD; Paul Nghiem, MD, PhD; Teri Heiland, PhD; | Novel Single-Agent Immunotherapies | Checkpoint blockade; Solid tumors; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Vaccine |
| 858 | Poster Presentation | A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies | Peter Ellmark, PhD; Karin Hägerbrand; Mattias levin; Laura Von Schantz, -; Adnan Deronic, PhD; Laura Varas; Anna Säll; Karin Barchan; Doreen Werchau, BS; Lill Ljug; Mia Thageson; Anna Rosen, MSc; Christina Sakellariou; Malin Lindstedt, PhD; | Novel Single-Agent Immunotherapies | Extracellular vesicles/exosomes; Antibody; Dendritic cell; Neoantigens; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| 859 | Poster Presentation | Inhibition of the kinase activity of Hematopoietic Progenitor Kinase 1 enhances anti-PD-1-induced reinvigoration of human tumor-infiltrating CD8+ T cells | Yongjoon Lee; Seung Hyuck Jeon; A Yeong Park; Suyeon Jo; Jinhwa Lee; Su-Hyung Park; Jamie Jae Eun Kim, PhD; Eui-Cheol Shin; | Novel Single-Agent Immunotherapies | Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs) |
| 860 | Poster Presentation | Targeting immunosuppressive macrophages overcomes PARP-inhibitor resistance in BRCA1-associated triple-negative breast cancer | Anita K. Mehta, PhD; Emily Cheney; Christina Hartl; Constantia Pantelidou; Madison Oliwa; Jessica Castrillon; Jia-Ren Lin; Katie E. Hurst; Mateus de Oliveira Taveira; Nathan Johnson; William Oldham; Marian Kalocsay; Matthew Berberich; Sarah Boswell; Aditi Kothari; Shawn Johnson, BS; Deborah Dillon; Mikel Lipschitz; Scott J. Rodig, MD, PhD; Sandro Santagata; Judy Garber; Nadine M. Tung, MD; José Yélamos; Jessica E. Thaxton, PhD, MS; Elizabeth A. Mittendorf, MD, PhD; Peter K. Sorger; Geoffrey I. Shapiro, MD, PhD; Jennifer L. Guerriero, PhD; | Novel Single-Agent Immunotherapies | Antibody; Immune suppression; Monocyte/Macrophage; Myeloid cells; Metabolism; Tumor microenvironment |
| 861 | Poster Presentation | Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells | Andrew Rankin, PhD; Edwina Naik, PhD; | Novel Single-Agent Immunotherapies | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| 862 | Poster Presentation | Targeting PSGL-1, a novel macrophage checkpoint, repolarizes suppressive macrophages, induces an inflammatory tumor microenvironment, and suppresses tumor growth | Phuong A. Nguyen, PhD; Ryan Phennicie; Kevin Kauffman, PhD; Dominika Nowakowska, PhD; Mohammad Zafari; Veronica Komoroski; Steve Sazinsky, PhD; Joe Wahle, PhD; Denise Manfra, PhD; Shantashri Vaidya, PhD; Michael A. Brehm, PhD; Igor Feldman, PhD; Tatiana Novobrantseva, PhD; | Novel Single-Agent Immunotherapies | Antigen presenting cells; Immune suppression; Monocyte/Macrophage; Myeloid cells; MDSC; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
